Creato in 2006 (Francia), I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome possiede 2757 marchi fratelli e 17478 marchi concorrenti. Il marchio I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome è di proprietà di SANOFI, una società quotata in Paris. Il codice identificativo della società in Borsa (ISIN) è FR0000120578. Il settore di I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome è Produttori di farmaci.

I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome è un marchio di SANOFI (SAN) novita

Deposito internazionale : 2006 Settori Produttori di farmaci

Tutta la situazione attuale Marketscreener Logo
SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome)

loader
Borsa: maggiori informazioni su SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome) Marketscreener Logo